glp-1 news today november 6 2025 Weight-loss drug makers announce pricing agreement with Trump GLP-1 Agonists Market Report 2025-2033,
Description
Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized.
GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential use in treating alcohol use disorder.
The American Society of Anesthesiologists (ASA) recommends withholding these drugs before surgery, but definitive guidelines remain unclear
Shop GLP3 Retatrutide 40mg, a triple-agonist peptide targeting GLP-1, GIP & Glucagon receptors
It helps maintain gut health, support metabolic performance, and promote immune and internal balance over time.
Considerations for employers who are thinking about covering GLP-1 drugs for weight loss.
